Tenderwize
Retour à la recherche

Open-House-Biologika-Rabattverträge 2024-10 - Pertuzumab / Trastuzumab (Wirkstoffkombination)

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 29, 2026 · 125 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-10 - Pertuzumab / Trastuzumab (Wirkstoffkombination)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

The procedure is explicitly not a public procurement under EU directive; legal challenges go to social courts, not proc...

Submission not via standard e-procurement portal; must be by email (with qualified electronic signature) or postal mail...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Enter into discount contracts for the drug combination Pertuzumab/Trastuzumab
  • No individual negotiations; uniform terms apply
Afficher le résumé complet

Open-House procedure by multiple German health insurance funds (Techniker Krankenkasse, HEK, hkk) to conclude discount contracts for the drug combination Pertuzumab/Trastuzumab (Biologics) under §130c SGB V. No exclusivity; any qualified pharmaceutical entrepreneur may join during the contract period. Uniform conditions; no individual negotiations. Contract duration max 24 months (01.01.2025 - 31.12.2026). Early termination upon patent expiry.

Risques

The procedure is explicitly not a public procurement under EU directive; legal challenges go to social courts, not proc...

Submission not via standard e-procurement portal; must be by email (with qualified electronic signature) or postal mail...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4(18) AMG
  • Valid marketing authorization for the drug(s) or other legal basis for placing on the market
  • Company seat must be in Germany, EU, or EEA

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2024-10 - Pertuzumab / Trastuzumab (Wirkstoffkombination)

Conclusion of discount contracts for Pertuzumab/Trastuzumab combination under §130c SGB V. Open to all qualified pharmaceutical entrepreneurs. Uniform contractual conditions, no exclusivity.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Dec 2024 - Dec 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 31, 2026

Détails de la procédure

Date de publication
13 Nov 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
694903-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3